Eight heterogeneous vancomycin-intermediate S. aureus (h-VISA) and seven VISA clinical isolates confirmed by the population analysis profile/area under the curve ratio (PAP/AUC) were collected. We further performed the PAP/AUC, time-killing methods and MIC tests using vancomycin/teicoplanin alone or combination with susceptible breakpoint concentrations of cefazolin, cefmetazole, cefotaxime, an...

Three different schemes of topography-based runoff production [versatile integrator of surface atmospheric processes (VISA)-TOP1, VISA-TOP2, and VISA-TOP3] are described for a land-surface model (LSM) developed for use with a general circulation model (GCM). The schemes’ sensitivities to some key parameters are assessed for two catchments using data sets developed for the Project for Intercompa...

Since vancomycin-intermediate Staphylococcus aureus (VISA) was first reported in Japan in 1997, there has been great concern that heterogeneous vancomycin-intermediate S. aureus (hetero-VISA) is the putative precursor of VISA. To investigate the prevalence, clinical significance, and molecular epidemiology of S. aureus with reduced susceptibility to vancomycin, all consecutive isolates of S. au...

INTRODUCTION AND PURPOSE VISA-P questionnaire assesses to severity of symptoms and treatment effects in athletes with patellar tendinopathy. The purpose of this study was to translated VISA-P questionnaire into Turkish language and to determine its validity and reliability. METHODS The English version of VISA-P questionnaire was translated into Turkish according to the internationally recomme...

We previously reported a novel phenotype of vancomycin-intermediate Staphylococcus aureus (VISA), i.e., "slow VISA," whose colonies appear only after 72 h of incubation. Slow-VISA strains can be difficult to detect because prolonged incubation is required and the phenotype is unstable. To develop a method for detection of slow-VISA isolates, we studied 23 slow-VISA isolates derived from the het...

Vancomycin has been used as the last resort in the clinical treatment of serious Staphylococcus aureus infections. Vancomycin-intermediate S. aureus (VISA) was discovered almost two decades ago. Aside from the vancomycin-intermediate phenotype, VISA strains from the clinic or laboratory exhibited common characteristics, such as thickened cell walls, reduced autolysis, and attenuated virulence. ...

VISA (also known as MAVS, IPS-1 and Cardif) is an essential adaptor protein in innate immune response to RNA virus. The protein level of VISA is delicately regulated before and after viral infection to ensure the optimal activation and timely termination of innate antiviral response. It has been reported that several E3 ubiquitin ligases can mediate the degradation of VISA, but how the stabilit...

conclusions there were diverse phenotypic changes among vancomycin-non-susceptible s. aureus isolates. this may be due to the variety of related regulatory systems. the diversity of phenotypic expression may result in its misidentification in routine laboratory checks. materials and methods a total of 130 methicillin-resistant s. aureus (mrsa) isolates were studied, including 49 vssa, 28 hvisa,...